Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions
Subrata Deb, Anthony Allen Reeves
Journal of Pharmacy & Pharmaceutical Sciences (2021) Vol. 24, pp. 277-291
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

ADME and Pharmacokinetic Properties of Remdesivir: Its Drug Interaction Potential
Subrata Deb, Anthony Allen Reeves, Robert Hopefl, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 7, pp. 655-655
Open Access | Times Cited: 64
Utility of PBPK Modeling in Predicting and Characterizing Clinical Drug Interactions
R. Foti
Drug Metabolism and Disposition (2024) Vol. 53, Iss. 1, pp. 100021-100021
Open Access | Times Cited: 9
The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination
David Baker, Eugenia Forte, Gareth Pryce, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 69, pp. 104425-104425
Open Access | Times Cited: 20
A newly developed high-performance thin layer chromatographic method for determination of remdesivir, favipiravir and dexamethasone, in spiked human plasma: comparison with the published methods
Rehab M. Abdelfatah, Esraa H. Abdelmomen, Eglal A. Abdelaleem, et al.
BMC Chemistry (2025) Vol. 19, Iss. 1
Open Access
Pharmacokinetic simulations for remdesivir and its metabolites in healthy subjects and patients with renal impairment
Shengjie Zhang, Seung Hee Jeong, Botao Jiang, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
From In Vivo Predictive Dissolution to Virtual Bioequivalence: A GastroPlus®-Driven Framework for Generic Candesartan Cilexetil Tablets
Hao Ruan, Xue Geng, Z Situ, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 4, pp. 562-562
Open Access
Unlocking the potential of remdesivir: innovative approaches to drug delivery
Maie S. Taha, Ahsan R. Akram, Ghada A. Abdelbary
Drug Delivery and Translational Research (2025)
Open Access
Biotransformation and transplacental transfer of the anti-viral remdesivir and predominant metabolite, GS-441524 in pregnant rats
Ling Yang, I-Hsin Lin, Lie‐Chwen Lin, et al.
EBioMedicine (2022) Vol. 81, pp. 104095-104095
Open Access | Times Cited: 12
Instruction of molecular structure similarity and scaffolds of drugs under investigation in ebola virus treatment by atom-pair and graph network: A combination of favipiravir and molnupiravir
Veysel Gider, Cafer Budak
Computational Biology and Chemistry (2022) Vol. 101, pp. 107778-107778
Closed Access | Times Cited: 12
Regulatory Requirements and Applications of Physiologically Based Pharmacokinetic Models
Marina Cuquerella-Gilabert, Matilde Merino‐Sanjuán, Alfredo García‐Arieta, et al.
(2024), pp. 193-219
Closed Access | Times Cited: 2
Improving ADMET Prediction Accuracy for Candidate Drugs: Factors to Consider in QSPR Modeling Approaches
Meilun Chen, Jie Yang, Chunhua Tang, et al.
Current Topics in Medicinal Chemistry (2023) Vol. 24, Iss. 3, pp. 222-242
Closed Access | Times Cited: 6
An Integrated Computational Approaches for Designing of Potential Piperidine based Inhibitors of Alzheimer Disease by Targeting Cholinesterase and Monoamine Oxidases Isoenzymes
Muhammad Sarfraz, Muhammad Ibrahim, Syeda Abida Ejaz, et al.
Applied Biochemistry and Biotechnology (2024) Vol. 196, Iss. 9, pp. 5875-5902
Closed Access | Times Cited: 1
Developing New Treatments for COVID-19 through Dual-Action Antiviral/Anti-Inflammatory Small Molecules and Physiologically Based Pharmacokinetic Modeling
Panagiotis Zagaliotis, Anthi Petrou, George A. Mystridis, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 14, pp. 8006-8006
Open Access | Times Cited: 6
Approaches of formulation bridging in support of orally administered drug product development
Murui Han, Jin Xu, Yiqing Lin
International Journal of Pharmaceutics (2022) Vol. 629, pp. 122380-122380
Closed Access | Times Cited: 6
Remdesivir-induced conduction abnormalities: A molecular model-based explanation
Ryan Kingsley, Christopher Rohlman, A. J. Otto, et al.
Journal of Pharmacy & Pharmaceutical Sciences (2023) Vol. 26
Open Access | Times Cited: 3
Simulation of drug-drug interactions between breast cancer chemotherapeutic agents and antiemetic drugs
Subrata Deb, Robert Hopefl
DARU Journal of Pharmaceutical Sciences (2023) Vol. 31, Iss. 2, pp. 95-105
Open Access | Times Cited: 3
Exploration of the optimal GS-441524 trough concentration for treating COVID-19
Yuki Nakano, Yoko Inokuchi, Tadashi Hayama, et al.
International Journal of Antimicrobial Agents (2023) Vol. 62, Iss. 2, pp. 106892-106892
Open Access | Times Cited: 3
Drug dosing in hospitalized obese patients with COVID-19
Jeffrey F. Barletta, Brian L. Erstad
Critical Care (2022) Vol. 26, Iss. 1
Open Access | Times Cited: 5
Drug Repurposing for COVID-19 using Computational Methods
Om Prakash, Feroz Khan
BENTHAM SCIENCE PUBLISHERS eBooks (2023), pp. 161-185
Closed Access | Times Cited: 2
A population pharmacokinetic model of remdesivir and its major metabolites based on published mean values from healthy subjects
Ahmed Abouellil, Muhammad Bilal, Max Taubert, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2022) Vol. 396, Iss. 1, pp. 73-82
Open Access | Times Cited: 3
Drug-Drug Interactions between COVID-19 and Tuberculosis Medications: A Comprehensive Review of CYP450 and Transporter-Mediated Effects
M. Rasheduzzaman Jony, Sangzin Ahn
Pharmaceuticals (2024) Vol. 17, Iss. 8, pp. 1035-1035
Open Access
Development and Validation of a Novel Rp-Hplc Method for Determination of Remdesivir: Investigation of the Greenness for the Proposed Method
Karthika Paul, B.H. Jaswanth Gowda, R. S. Chandan
(2024)
Closed Access
Pharmacogenetics of antiviral agents for the treatment of COVID-19
И. И. Темирбулатов, А. V. Kryukov, Д. А. Сычев
Pharmacogenetics and Pharmacogenomics (2022), Iss. 1, pp. 38-41
Open Access | Times Cited: 2
Significant Prolongation of the International Normalized Ratio Associated with COVID-19 Treatment: Possible Drug Interaction with Remdesivir
Hidetoshi Ishii, Norio Yokota, Yuki Bando, et al.
YAKUGAKU ZASSHI (2022) Vol. 142, Iss. 10, pp. 1125-1127
Open Access | Times Cited: 1
The Effect of Carriage of <i>CYP3A5*3</i> and <i>CYP3A4*22</i> Polymorphic Variants on the Safety of Remdesivir Therapy in Patients with COVID-19
И. И. Темирбулатов, А. V. Kryukov, К. Б. Мирзаев, et al.
Antibiot Khimioter = Antibiotics and Chemotherapy (2022) Vol. 67, Iss. 7-8, pp. 45-50
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top